Newsroom | 58655 results

COLLEGE PARK (Maryland), USA.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), världens ledande kvantdatorföretag, tillkännagav i dag ett utökat samarbetsavtal med QuantumBasel, kvantinitiativet vid uptownBasel, Schweiz internationella innovationscampus. Genom det utökade avtalet beviljas QuantumBasel äganderätten till det befintliga IonQ Forte Enterprise-systemet och blir ägare av ett nästa generationens Tempo-system. Det nya avtalet ökar det totala värdet av samarbetet mellan QuantumBasel och IonQ till ö...

NORTHBROOK, Ill.--(BUSINESS WIRE)--UL Solutions Inc. (NYSE: ULS) (“UL Solutions”) today announced, in connection with its previously announced secondary public offering of 12,500,000 shares of its Class A common stock sold by UL Standards & Engagement (the “selling stockholder”), the full exercise by the underwriters of their option to purchase 1,875,000 additional shares of Class A common stock from the selling stockholder at the public offering price of $78.00 per share, less underwriting...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity award...

DUBLIN--(BUSINESS WIRE)--The "Central Nervous System Therapeutics Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Central Nervous System Therapeutics was valued at US$107 Billion in 2024 and is projected to reach US$156.5 Billion by 2030, growing at a CAGR of 6.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. T...

WASHINGTON--(BUSINESS WIRE)--Orano and Perpetual Atomics announced an agreement to develop a supply of americium-241 (Am-241) sourced from Orano’s La Hague spent nuclear fuel reprocessing site in France. Perpetual Atomics, a leader in radioisotope and space nuclear power technologies, is excited to announce that via this partnership, the processing of americium into sealed sources for use in its portfolio radioisotope power systems will expand. This expansion will support a broadening customer...

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (Sede: Chuo-ku, Tokyo; Presidente e CEO: Toshiaki Nagasato) oggi ha annunciato la firma di un accordo di collaborazione con MBC BioLabs, un'organizzazione privata che supporta lo sviluppo di aziende startup biotecnologiche nella San Francisco Bay Area californiana. MBC BioLabs fornisce strutture di ricerca completamente attrezzate e una comunità di supporto che aiuta gli imprenditori del settore biotecnologico ad accelerare le operazioni dal...

TOKIO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (hoofdkantoor: Chuo-ku, Tokio; president en CEO: Toshiaki Nagasato) heeft vandaag bekendgemaakt dat het een samenwerkingsovereenkomst heeft gesloten met MBC BioLabs, een particuliere organisatie die de ontwikkeling van biotechnologische start-ups in de San Francisco Bay Area in Californië ondersteunt. MBC BioLabs biedt volledig uitgeruste onderzoeksfaciliteiten en een ondersteunende gemeenschap die biotechondernemers helpt om sneller van conc...

TOKIO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (sede central: Chuo-ku, Tokio; presidente y gerente general: Toshiaki Nagasato) ha anunciado hoy que ha suscrito un acuerdo de colaboración con MBC BioLabs, una organización privada que sustenta el desarrollo de las empresas emergentes de biotecnología en el área de la bahía de San Francisco, en California. MBC BioLabs ofrece instalaciones de investigación totalmente equipadas y una comunidad de apoyo que asiste a los emprendedores biotecnoló...

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (siège : Chuo-ku, Tokyo ; président-directeur général : Toshiaki Nagasato) a annoncé aujourd’hui avoir conclu un accord de partenariat avec MBC BioLabs, une organisation privée qui soutient le développement de startups biotechnologiques dans la région de la baie de San Francisco, en Californie. MBC BioLabs fournit des installations de recherche entièrement équipées et une communauté solidaire qui aide les entrepreneurs biotechnologiques à pas...

TOKIO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (Hauptsitz: Chuo-ku, Tokio; President & CEO: Toshiaki Nagasato) gab heute bekannt, dass eine Partnerschaftsvereinbarung mit MBC BioLabs unterzeichnet wurde, einer Privatfirma, die die Entwicklung von biotechnischen Startup-Unternehmen in der Umgebung der San Francisco Bay im US-Bundesstaat Kalifornien unterstützt. MBC BioLabs stellt vollumfänglich ausgestattete Forschungsanlagen und eine unterstützende Gemeinschaft bereit, die biotechnisc...